Please Wait.....
Report
Therapeutic mRNA Patent Landscape Report and Forecast 2024-2032
Market Report I 2024-08-29 I 200 Pages I EMR Inc.
Global Therapeutic mRNA Patent Landscape Report 2024
Global Therapeutic mRNA Industry Size
The global therapeutic mRNA market was valued at USD 13.23 billion in 2023. It is expected to grow at a CAGR of 14.56% during the forecast period of 2024-2032 and attain a market value of USD 45 billion by 2032. The patent landscape is shaped by key innovations in lipid nanoparticles, polymer-based delivery systems, chemical modifications for mRNA stability, and mRNA-based cancer immunotherapies, resulting in a surge of patent applications in these areas.
Patent Landscape Report Coverage
The therapeutic mRNA patent landscape report delves into the dynamic and rapidly evolving patent landscape of therapeutic mRNA. It highlights key innovations in lipid nanoparticles and polymer-based delivery systems, chemical modifications for mRNA stability, and mRNA-based cancer immunotherapies. The report provides a comprehensive analysis of patent filings segmented by design, route of administration, and indication, showcasing leading regions such as the United States, Europe, and Asia. It also profiles major players like Pfizer, Novartis, and Genentech, detailing their patent activities and contributions to advancing mRNA therapies.
Global Therapeutic mRNA Patent Outlook
- The therapeutic mRNA market is driven by the rising incidence of chronic diseases and technological advancements in mRNA delivery and stability. Innovations in lipid nanoparticles and polymer-based systems enhance mRNA therapy efficacy, broadening its applications in personalised medicine and vaccines.
- Numerous biotech firms and academic institutions are actively filing patents in the therapeutic mRNA landscape. Pfizer, Novartis, and Genentech are leading the charge with extensive patents on mRNA stability, delivery methods, and therapeutic applications. Their contributions are pivotal in advancing mRNA therapies for various diseases, including cancer and infectious diseases.
- The US leads the patent landscape for therapeutic mRNA, with Germany, the UK, and France focusing on enhancing mRNA modifications and immunogenicity. The Asia Pacific region, particularly China and Japan, is emerging as a key player with numerous patents on cost-effective production methods and novel therapeutic applications. These regions are poised to dominate the patent landscape in the future due to advancements in delivery systems, stability enhancements, and therapeutic efficacy.
Therapeutic mRNA Introduction
Therapeutic mRNA represents a revolutionary approach in modern medicine, using messenger RNA to instruct cells to produce specific proteins that can treat or prevent diseases. Unlike traditional gene therapy, mRNA therapies do not alter the patient's DNA, offering a safer alternative. These therapies have shown immense potential in various fields, including vaccines, cancer treatment, and rare genetic disorders. The rapid development and success of mRNA COVID-19 vaccines have accelerated research and investment in this area. As technology advances, therapeutic mRNA is poised to transform the landscape of personalised medicine, providing targeted, efficient, and adaptable treatment options.
Patents on novel lipid nanoparticles and polymer-based delivery systems are driving the therapeutic mRNA market. These innovations enhance mRNA stability and cellular uptake, improving the efficiency of mRNA therapies. Continuous patent activity in this area reflects ongoing efforts to overcome delivery challenges, expanding the therapeutic potential of mRNA.
- Increasing patents focusing on chemical modifications to improve mRNA stability are shaping the market. These patents cover techniques such as pseudouridine incorporation and 5-methylcytosine modifications. Such advancements ensure sustained protein expression, enhancing the efficacy of mRNA therapies and reflecting significant patent activity aimed at improving therapeutic outcomes.
- Patents on mRNA-based cancer immunotherapies are expanding the landscape. These innovations focus on using mRNA to produce tumour antigens that stimulate the immune system. The surge in patent filings in this area highlights the growing interest in mRNA as a versatile tool for personalized cancer treatment.
These drivers create a dynamic, rapidly evolving therapeutic mRNA patent landscape, fostering innovation and expanding applications in advanced delivery systems, enhanced stability, cancer immunotherapy, and broadening vaccine development.
Global Therapeutic mRNA Patent Segmentation Analysis
The report provides an in-depth analysis of the patents in this field by the following segmentation -
Analysis by Design
- Self-Amplifying mRNA
- Conventional non-Amplifying mRNA
The patent segments in the global therapeutic mRNA market by design, specifically self-amplifying mRNA and conventional non-amplifying mRNA, demonstrate notable advancements. Self-Amplifying mRNA leads the patent landscape with over 400 patents historically filed and 150 currently in process. These patents drive innovations in amplifying the therapeutic effect of mRNA treatments, enhancing their efficacy. Such advancements are expected to drive future growth, solidifying the role of self-amplifying mRNA in expanding the therapeutic potential and broadening the applications of mRNA technologies in personalised medicine and vaccine development.
Analysis by Route of Administration
- Intravenous
- Intramuscular
- Others
The patent segments in the therapeutic mRNA industry by route of administration, specifically intravenous, intramuscular, and others, demonstrate notable advancements. Intravenous administration leads the patent landscape with over 500 patents historically filed and 200 currently in process. These patents are driving improvements in mRNA delivery systems and bioavailability. Ongoing innovations are expected to boost the clinical success of intravenous mRNA therapies, broadening their application scope in treating various diseases and enhancing therapeutic outcomes.
Analysis by Indication
- Oncology
- Infectious Diseases
- Autoimmune Diseases
- Others
The patent segments in the therapeutic mRNA industry by indication, specifically oncology, infectious diseases, autoimmune diseases, and others, demonstrate notable advancements. Oncology leads the patent landscape with over 600 patents historically filed and 250 currently in process. These patents drive innovations in targeted mRNA treatments for cancer, aiming to improve precision and treatment effectiveness. Ongoing developments are expected to significantly enhance cancer therapy options, advancing patient care and solidifying the pivotal role of mRNA technology in oncology.
Therapeutic mRNA Patent Jurisdiction Analysis
The global patent landscape for therapeutic mRNA is rapidly evolving, with significant activity in the United States, Europe, and Asia. Each region reveals unique trends in patent filings and corporate involvement, reflecting regional priorities and advancements in this innovative technology.
- The United States leads the patent landscape for therapeutic mRNA with over 700 patents filed. This leadership is driven by substantial investment in biotechnology and a supportive regulatory framework. Key patents focus on advanced delivery systems and mRNA stability, reflecting the country's commitment to pioneering mRNA-based therapies.
- Europe holds approximately 600 patents in the therapeutic mRNA sector, with significant contributions from Germany, the UK, and France. European patents often emphasise innovations in mRNA modifications and immunogenicity enhancements. Collaborative research initiatives and strong funding support these advancements, highlighting Europe's role in advancing mRNA technology for medical applications.
- Asia, particularly China and Japan, has around 500 patents related to therapeutic mRNA. Rapid technological advancements and robust government support for biotech research drive significant patent activity in this region. Asian patents typically focus on cost-effective production methods and novel therapeutic applications, showcasing the region's growing influence in the global mRNA landscape.
Patent Profile of Key Companies
The patent landscape for therapeutic mRNA is shaped by several key companies driving innovation and securing intellectual property. Here is an overview of their patent activities.
Pfizer, Inc.:
Pfizer, Inc. holds a leading position in the therapeutic mRNA patent landscape, with numerous patents focused on vaccine development and delivery systems. Their innovations drive advancements in mRNA stability and immune response optimisation.
Novartis AG:
Novartis AG has a robust portfolio in therapeutic mRNA, emphasising cancer immunotherapy and personalized medicine. Their patents focus on innovative mRNA delivery methods and therapeutic applications, enhancing treatment precision and efficacy.
Genentech Inc.:
Genentech Inc. is a key player in the therapeutic mRNA patent landscape, with patents centred on advanced mRNA formulations and delivery technologies. Their contributions are pivotal in developing targeted mRNA therapies for various diseases, including oncology and genetic disorders.
Other key players in the industry include Amgen Inc., Regeneron Pharma.
Key Questions Answered in the Global Therapeutic mRNA Patent Landscape Report
- What are the implications of patent filings in therapeutic mRNA?
- What are the challenges and opportunities in the therapeutic mRNA patent landscape?
- What are the regulatory and legal considerations?
- What are the major global trends in therapeutic mRNA patents?
- Which regions are leading in therapeutic mRNA patent filings?
- What drives the therapeutic mRNA patent landscape?
- How do self-amplifying mRNA patents differ from conventional ones?
- What advancements are notable in mRNA administration routes?
- Which diseases are most targeted in mRNA patents?
- What are the key patent activities of major companies?
- How do patent trends vary by region?
- What chemical modifications are significant for mRNA stability?
- How is the therapeutic mRNA patent landscape expected to change?
- What is the technological focus of patents in the therapeutic mRNA industry?
Reasons to Purchase this Report
This report provides a comprehensive analysis of the global therapeutic mRNA patent landscape, covering market size, growth trends, and technological advancements. It offers detailed insights into patent segmentation by type and application, highlighting key areas of innovation and activity. By examining the strategies and patent portfolios of leading companies, the report elucidates competitive dynamics and emerging opportunities. Stakeholders will gain valuable information on patent trends, regional developments, and technological breakthroughs, aiding strategic decision-making and fostering advancements in therapeutic mRNA.
1 Introduction
2 Executive Summary
3 Global Therapeutic mRNA Market Overview
3.1 Global Therapeutic mRNA Market Historical Value (2017-2023)
3.2 Global Therapeutic mRNA Market Forecast Value (2024-2032)
4 Global Therapeutic mRNA Market Segmentation
4.1 Global Therapeutic mRNA Market Share by Design
4.1.1 Market Overview
4.1.2 Self-Amplifying mRNA
4.1.3 Conventional Non-Amplifying mRNA
4.2 Global Therapeutic mRNA Market Share by Route of Administration
4.2.1 Market Overview
4.2.2 Intravenous
4.2.3 Intramuscular
4.2.4 Others
4.3 Global Therapeutic mRNA Market Share by Indication
4.3.1 Market Overview
4.3.2 Oncology
4.3.3 Infectious Diseases
4.3.4 Autoimmune Diseases
4.3.5 Others
5 Global Market Dynamics
5.1 Market Drivers and Constraints
5.2 Porter's Five Forces Analysis
5.3 PESTEL Analysis
5.4 Industry Events, Initiatives, and Trends
5.5 Value Chain Analysis
6 Global Therapeutic mRNA Patent Landscape Analysis
6.1 Patent Distribution by Publication Year
6.2 Patent Distribution by Application Year
6.3 Patent Distribution by Priority Year
6.4 Analysis by Type of Patent
6.4.1 Granted Patents
6.4.2 Patent Application
6.4.3 Amended Application
6.4.4 Search Report
6.5 Analysis by Legal Status
6.5.1 Active
6.5.2 Pending
6.5.3 Expired/Discontinued
6.6 Analysis by Patent Jurisdiction
6.7 Analysis by Patent Age
6.8 Analysis by Cooperative Patent Classification (CPC) Codes
6.9 Average Time to Publish a Patent
6.9.1 By Entities
6.9.2 By Jurisdiction
6.9.3 By Technology
6.10 Analysis by Type of Entity (Academic and Non-Academic)
6.11 Analysis by Top Applicants
6.12 Analysis by Top Inventors
7 Global Therapeutic mRNA Patent Analysis by Technology
7.1 Total Patents by Top Technologies
7.2 Time Evolution of Patents by Technology
7.3 Emerging Technologies
7.4 Patent Segmentation, By mRNA Design
7.4.1 Time Evolution by Number of Patents
7.4.2 Time Evolution by Number of Patent Families
7.4.3 Analysis by Type of Entity (Academic vs Non-Academic)
7.4.4 Analysis by Top Applicants
7.4.5 Analysis by Top Inventors
7.5 Patent Segmentation, By mRNA Delivery
*Complete technology list will be provided in the report.
8 EMR Patent Valuation Analysis
8.1 Assessment Methodology
8.2 High Value Patents
8.3 Medium Value Patents
8.4 Low Value Patents
9 Global Therapeutic mRNA - Top 10 Players Patent Analysis
9.1 Top 10 Entities by Number of Patents
9.2 Analysis by Publication Year
9.3 Analysis by Application Year
9.4 Analysis by Priority Year
9.5 Analysis by Type of Patent
9.6 Analysis by Jurisdiction
9.7 Analysis by Cooperative Patent Classification (CPC) Codes
9.8 Analysis by Source of Innovation
9.9 Analysis by Forward and Backward Citations
9.10 Analysis by Legal Status
9.11 Analysis by Patent Age
9.12 Analysis by Key Inventors
9.13 Entity Dynamics
9.13.1 Analysis by Type of Player (Academic vs Non-Academic)
9.13.2 Analysis by Collaboration
9.13.3 Analysis by Technology
9.13.4 Newcomers
9.13.4.1 Start-up Companies
9.13.4.2 Established Companies
10 Patent Profile of Key Players
10.1 Pfizer, Inc .
10.1.1 Product Portfolio
10.1.2 Patent Portfolio by Patent Families
10.1.3 Time Evolution of Patents
10.1.4 Geographical Patent Coverage
10.1.5 Patent Analysis by Technology
10.1.6 Patent News and Developments
10.1.7 Financial Analysis
10.1.8 SWOT Analysis
10.2 Novartis AG
10.3 Genentech Inc.
10.4 Amgen Inc.
10.5 Regeneron Pharma
11 Future Trends
12 Global Therapeutic mRNA Landscape (Additional Insight)*
12.1 Global Therapeutic mRNA: Developers Landscape
12.1.1 Analysis by Year of Establishment
12.1.2 Analysis by Company Size
12.1.3 Analysis by Region
12.2 Global Therapeutic mRNA: Product Landscape
12.2.1 Analysis by Type
12.2.2 Analysis by Route of Administration
12.2.3 Analysis by Therapeutic Area
*Additional insights are not provided in the standard report.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security